{"id":"W2594529508","doi":"10.1016/s1470-2045(17)30180-8","title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":491,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Dacarbazine; Medicine; Neuroblastoma RAS viral oncogene homolog; Hazard ratio; Melanoma; Internal medicine; Clinical endpoint; Population; Adverse effect; Oncology; Progression-free survival; Randomized controlled trial; Vemurafenib; Cancer; Confidence interval; Chemotherapy; Metastatic melanoma; Cancer research; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001090091,0.001566223,0.002195093,0.0002578353,0.0003387462,0.001049009,0.0006212459,0.001164344,0.005276829],"category_scores_gemma":[0.001028892,0.0005082694,0.001701667,0.0003356217,0.0008511774,0.001179805,0.0004305122,0.00315426,0.0008562604],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008750187,"about_ca_system_score_gemma":0.0006803627,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001051057,"about_ca_topic_score_gemma":0.003370733,"domain_scores_codex":[0.9996853,0.000149741,0.00001296783,0.0000540892,0.00002190712,0.00007601962],"domain_scores_gemma":[0.9995885,0.00009496821,0.00008555307,0.00002969172,0.00002192239,0.0001793123],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9669834,0.003071584,0.0007732742,0.0006593236,0.001165749,0.00005169411,0.0000794259,0.0007177944,0.003389788,0.0001677135,0.001290388,0.02164985],"study_design_scores_gemma":[0.942104,0.05258199,0.00240162,0.00005215643,0.0004144834,0.00006822674,0.00004682715,0.0004856678,0.0003248769,0.0003747268,0.001126075,0.00001922558],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868499,0.006215176,0.0005420602,0.001236704,0.0006123555,0.001323702,0.0009218091,0.00008536401,0.002213067],"genre_scores_gemma":[0.9869363,0.003728971,0.0009371248,0.001289376,0.0002864495,0.001322463,0.001148756,0.00002876084,0.004321835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005276829,"threshold_uncertainty_score":0.01765275,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05756250214883237,"score_gpt":0.3665577832550817,"score_spread":0.3089952811062494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}